On-Demand CME Videos
Open Up to New Treatments for Vitiligo: Online CME Activity
About
This activity was recorded at the Winter Clinical Dermatology Conference-Hawaii on January 17, 2023
CME Seminar in Depth - Open Up to New Treatments for Vitiligo
This activity is supported by an educational grant from Incyte.
Availability
In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:
January 17, 2023
January 17, 2024
Learning Objectives
At the completion of this activity, participants should be better able to:
Recall the clinical trial data on JAK inhibitors for the management of vitiligo
Describe strategies to manage AE associated with JAK inhibitors
Discuss how to utilize JAK inhibitors in clinical practice for the management of vitiligo
Intended Audience
Faculty
Seemal Desai, MD
Clinical Assistant Professor
Department of Dermatology
University of Texas Southwestern Medical Center
Dallas, TX
Susan Taylor, MD
Incoming President-elect, American Academy of Dermatology
Bernett L. Johnson Endowed Professor in Dermatology
Perelman School of Medicine, University of Pennsylvania
Philadelphia, PA
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada and CMEsquared. The University of Nevada is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Nevada designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
CONFLICTS OF INTEREST/DISCLOSURES
In accordance with the ACCME Standards for Commercial Support, balance, independence, objectivity, and scientific rigor are ensured in all CME activities. This requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with any ineligible companies. In addition, the content of this material has been approved by an independent peer reviewer.
Disclosures are as follows:
Grant/Research Support: AbbVie, Incyte, Dermavant, AOBiome,
Consultant: Galderma, Almirall, Ferndale, BMS, AbbVie, Verrica, UCB, Ortho, Scientis, EPI, Avita, Eli Lilly, Leo, Pfizer, Incyte, L’Oreal, Beiersdorf, J&J
Speakers’ Bureau or Honoraria: Dermavant, Galderma, Pfizer
The planners have disclosed that they have no relevant financial relationships with any Ineligible Company in the past 24 months.
The University of Nevada discloses that all relevant conflicts have been satisfactorily mitigated.